Abbott Laboratories ABT
-
Why Abbott Is A Buy After The Lawsuit
… industry is a defense play, just like the food and beverages industry, in terms of sensitivity and market beta. Abbott Laboratories ( ABT ) is uniquely situated in the industry because of its growth prospects and because it still has a reduced valuation …
-
Brief Review Of A Few Biotechs
… Shaker : The following is a review of three biotech stocks with potential for growth. Amarin ( AMRN ), Osiris (OSIR and Abbott ( ABT ) are three companies with either recent breakthroughs, a catalyst, or a possible place to ride out a coming storm. Amarin …
-
Abbott Is Cheap, But AbbVie Will Likely Be Cheaper
strong>By The Dumb Money : Background : I bought my first shares of Abbott ( ABT ) on April 13, 2010 at $52.44/share. As of Friday's close the total return of ABT thus far has beaten the S&P Total …
-
New Morningstar Analyst Report - Hospira, Inc.
… company's profits. Hospira's cost-cutting measures and rising profitability since it's spin-off from Abbott Laboratories ABT in 2004 have come to a halt after becoming mired in FDA regulatory issues related to product quality. Despite …
-
Yield, Value, Safety: Are They Still Available For Big Pharma? (Part 2)
… Holdings LTD ADR (RHHBY), $120 billion (mega cap, Switzerland) Merck & Co ( MRK ), $116 billion (mega cap, U.S.) GlaxoSmithKline PLC ADR ( GSK ), $116 billion (mega cap, U.K.) Abbott Labs ( ABT ), $98 Complete Story »
-
Myrexis Undervalued As BioPharma Transforms
By Takeover Analyst : From Pfizer ( PFE ) selling off non-core assets to Abbott Laboratories ( ABT ) initiating a spin-off, BioPharma has been in full strategic mode. There are four key reasons for this transition: (1 …
-
Can Teva Win With The Big Pharma Playbook?
… And just for good measure, a few outliers like Endo Pharmaceuticals ( ENDP ) add devices to the mix, while others like Abbott ( ABT ) and Covidien ( COV ) look to split and spin-off their drug businesses. What's the point? Well, mostly that Teva probably …
-
More on Depomed (DEPO): Q1 beats across the board on fewer than anticipated losses, despite an 80% Y/Y decline in total revenue, largely attributed to licensing revenue and a milestone payment from ...
More on Depomed ( DEPO ): Q1 beats across the board on fewer than anticipated losses, despite an 80% Y/Y decline in total revenue, largely attributed to licensing revenue and a milestone payment from Abbott Labs . Shares -0.4% AH. Post your comment!
-
Bright Future Ahead Of Abbott Despite Mounting Competition
By Muhammad Bazil : Abbott ( ABT ) is one of the movers and shakers in America's mainstream drug manufacturing industry. Nested on a market cap of $97 billion …
-
Abbott: New Reasons The Split Could Tank Stock
By Dividend Kings : Abbott Laboratories ( ABT ) has announced that it will split in two by the end of 2012. One half will be a diversified medical products company, while …